The New Sourcing Map for U.S. Importers in 2026

Three years ago, the “China+1” strategy, maintaining Chinese sourcing while adding at least one alternative country to reduce concentration risk, was an emerging concept being discussed in board rooms. Today it is the operational baseline for U.S. importers. According to recent industry data, nearly 79% of companies have moved at least some sourcing volume away from China during 2025, and more than 40% plan to expand that diversification further in 2026. The question has shifted from “should we diversify?” to “where, by what category, and how much?”

This article looks at where the diversification is going, what is driving the country-specific patterns, and what U.S. importers should understand about the supply chain landscape that is emerging from years of restructuring.

Why the Shift Has Accelerated

Several factors converged in 2025 and 2026 to push China+1 from a strategic discussion to an operational reality:

Tariff Pressure

The cumulative effect of Section 301 tariffs, the IEEPA tariffs (now invalidated by the Supreme Court), the Section 122 universal tariffs, and the Section 232 pharmaceutical tariffs is that China-origin goods carry materially higher landed costs than equivalent goods from most alternative sources. For many product categories, the tariff differential alone justifies sourcing reallocation.

Section 301 Findings

Initial Section 301 findings issued recently have begun providing clarity on the post-July 24 tariff environment. The first round of findings (labor enforcement) assigned 12.5% rates to 46 countries and 10% rates to 14 others. The remaining overcapacity investigation, affecting 16 countries, is still pending. The rates announced so far are meaningful but not catastrophic, falling roughly in line with the previous Section 122 levels rather than at the IEEPA peaks of 15–18%.

Supply Chain Risk Awareness

The Middle East conflict, the Strait of Hormuz disruption, and the ongoing fragility of just-in-time supply chains have made supply chain resilience a board-level concern, not just an operational one. Sourcing concentration in any single country, particularly one with the geopolitical exposure China carries, is increasingly treated as strategic risk rather than as an optimization choice.

Regulatory Pressure

The BIOSECURE Act (now law via Section 851 of the FY 2026 NDAA), the Section 232 pharmaceutical tariff regime, FDA data integrity enforcement, and CBP forced labor enforcement (particularly under the UFLPA) have all increased the regulatory cost of China sourcing across multiple industries simultaneously.

The result is that diversification away from China has stopped being a question of strategy and started being a question of execution. Specifically, which alternative sources fit which product categories, and what the supply chain restructuring actually costs.

Where the Volume Is Going

The sourcing patterns reflect specialization rather than a single replacement source for China. Vietnam has absorbed the largest share of consumer goods, apparel, and electronics. India has become the default for pharmaceutical and chemical diversification. Malaysia is critical for semiconductor and medical device sourcing. Morocco has emerged as an EU-focused alternative across automotive, textiles, and aerospace.

For U.S. importers, the practical implication is that effective sourcing diversification is not a single-country decision. It is a portfolio of country-specific bets, with each one selected for its match to particular product categories, regulatory requirements, and freight realities.

The Catch: Most Alternative Sources Still Depend on China

The most important structural fact about current sourcing diversification, and one that is easy to miss in the headline numbers, is that most alternative sources retain meaningful upstream supply chain dependence on China.

Vietnamese electronics assembly often uses Chinese components. Indian pharmaceutical manufacturing depends heavily on Chinese KSMs and intermediates. Industry estimates suggest India still imports 65–70% of its bulk drug intermediates from China. Malaysian semiconductor packaging uses Chinese raw materials. Morocco’s automotive assembly draws on Chinese components routed through European supply chains.

This does not mean diversification is illusory. The Tier 1 manufacturing location matters for tariff exposure, for compliance treatment, for FDA inspection oversight, for customs documentation, and for geopolitical risk reduction. A product made in Vietnam from Chinese inputs is not the same as a product made in China for any of these compliance and operational purposes.

But importers planning multi-year sourcing strategies should understand the full molecular passport of what they are buying. The China-content question matters operationally in several ways:

• Transshipment and circumvention enforcement: CBP has stepped up scrutiny of goods routed through third countries primarily to avoid Chinese-origin tariff treatment. Substantial transformation rules are being enforced more rigorously.
• BIOSECURE Act compliance: for life sciences companies, upstream Chinese supplier exposure matters if any vendor in the synthesis chain becomes a designated biotechnology company of concern.
• Forced labor enforcement: UFLPA applies to goods anywhere in the supply chain with exposure to designated regions, regardless of final assembly location.
• Future tariff exposure: country-specific tariff treatment can evolve over time. A current 12.5% rate is not a permanent feature of the trade landscape.

Practical Guidance for U.S. Importers

1. Match Sources to Categories, Not the Other Way Around

The most common sourcing diversification mistake is choosing a destination country first and then trying to source product categories there. The better approach is to start with the product category and identify which destination markets are well-suited for it. Vietnam is excellent for apparel and consumer electronics; it is not necessarily the right destination for specialized industrial equipment. India is the right destination for pharmaceutical APIs and complex generics; it is not necessarily the right destination for high-end electronics manufacturing.

2. Model Total Landed Cost, Not Just Unit Cost

Headline cost comparisons across sourcing destinations are misleading. The complete picture includes tariff exposure, freight costs (Asia-Pacific freight rates remain elevated in 2026), compliance overhead, lead time variability, quality cost, and inventory carrying cost. Indian pharmaceutical APIs may carry lower duty exposure but higher air freight cost; Vietnamese electronics may have shorter lead times but higher manufacturing cost. Total landed cost analysis at the SKU level is the only reliable basis for sourcing decisions.

3. Understand Your Upstream Supply Chain

Ask alternative suppliers where their inputs come from. The answer may not change your sourcing decision, but it should inform your risk modeling and compliance strategy. Suppliers who cannot or will not document their upstream supply chain should be treated as carrying elevated risk.

4. Build Customs and Compliance Capacity

Sourcing from multiple new countries simultaneously increases compliance complexity in proportion. HTS classification, country of origin determinations, FDA Prior Notice requirements, USMCA documentation, and forced labor compliance documentation all require expert handling. Importers who handled their previous China-concentrated sourcing through informal processes often need to upgrade their customs and compliance infrastructure during diversification.

5. Maintain Multi-Source Optionality

The most sophisticated importers are not replacing China concentration with new concentration in Vietnam, India, or Malaysia. They are building portfolio approaches that distribute volume across multiple sources, with the operational capacity to shift between them as conditions change. The goal of diversification is reduced risk, not just lower current cost.

How Euro-American Worldwide Logistics Supports Sourcing Diversification

Euro-American Worldwide Logistics works with importers managing the operational reality of diversified international sourcing, multiple countries, multiple compliance regimes, multiple freight relationships, and the increased customs complexity that comes with it. Our licensed U.S. Customs Brokerage handles HTSUS classification, country of origin determinations, and entry filings across the full range of sourcing destinations. Our international freight forwarding network supports air and ocean freight from established and emerging sourcing markets worldwide.

For life sciences importers in particular, our integrated cGMP-compliant warehousing provides the validated temperature-controlled infrastructure that pharmaceutical and biotech supply chains require regardless of origin country.
For questions about how to operationalize a diversified sourcing strategy, contact our team.

---

Sources include the LogisticsPULSE June 2026 Executive Briefing; sourcing data compiled from Forbes, IBEF, Maersk, and TradeInt; and various 2026 industry analyses of China+1 sourcing patterns.